CAR-T cell therapy has achieved important breakthroughs in the treatment of some solid tumors. CAR-T cell clinical trials, targeting several antigens expressed in tumors of different organs, are registered on clinicaltrials.gov and summarized in Table1. The common CAR-T cell targets in solid tum...
Nowadays, identifying and defeating the mechanisms associated with CAR T cell dysfunction is crucial to establish CAR T cells that can proliferate and lyse tumor cells severely. In this review, we discuss the CAR signaling and efficacy T in solid tumors and evaluate the most significant barriers ...
CAR-T cell therapy has achieved important breakthroughs in the treatment of some solid tumors. CAR-T cell clinical trials, targeting several antigens expressed in tumors of different organs, are registered on clinicaltrials.gov and summarized in Table1. The common CAR-T cell targets in solid tum...
J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020). PubMed Google Scholar Wagner, J., Wickman, E., DeRenzo, C. & Gottschalk, S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol....
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application in solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cytotoxicity of
Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager. Cancer Immunol. Res. 6, 605–616 (2018). CAS PubMed PubMed Central Google Scholar Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable...
-- Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armored CAR T cell designs may bridge the gap from liquid to solid tumors Dr. Renier Brentjens, 细胞治疗中心主任,美国纪念斯隆-凯特琳癌症中心, 科学创始人,美国朱诺治疗公...
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surround
This technology has generated multiple apparent cures in the treatment of B-cell malignancies, but has had much less impact in solid tumors. This perspective article considers the prior experience and the future possibilities for extending this technology's potential to the much more numerous solid ...
CAR T cells releasing IL-18 convert to T-bethighFoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205–3219 (2017). Article CAS PubMed Google Scholar Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy ...